Azacitidine (Vidaza)

Hypomethylating agent used in combination with Venetoclax for Aml treatment. Started approximately December 2025. Last cycle: 2026-04-06 to 2026-04-13.

Dose

Dose not documented in raw sources — prescription documents needed. Standard dosing for AML is typically 75 mg/m2 subcutaneous or IV daily for 7 days of a 28-day cycle.

Schedule History

Azacitidine has been given for 5 days per cycle since at least Cycle 2 (2026-01-19). This is a reduction from the standard 7-day schedule. The 5-day schedule was initially reported only for Cycle 4+ (Apr 2026), but patient report confirms it was also used in Cycle 2 (Jan 2026). Whether Cycle 1 (Dec 2025) used 5 or 7 days is not yet confirmed.

Route of Administration

As of 2026-03-30, Dr. Bijay discussed with the patient whether she prefers subcutaneous azacitidine versus IV administration. The most recent cycle (Cycle 4+, 2026-04-06 to 2026-04-13) was administered IV. This resolves the route discussion — IV was chosen. Source: patient report, 2026-04-15; WhatsApp message, 2026-03-30.

Observed Side Effects

• Myelosuppression: WBC nadir 1300, ANC nadir 610 in February 2026. Pancytopenia is expected with this regimen but requires close monitoring for infection risk during nadir periods.
• Hyponatremia: Possible contribution to persistent Hyponatremia observed since January 2026 (see Sodium, Chloride).

Monitoring

• CBC with differential before each cycle and at nadir
• Renal function and electrolytes (sodium, potassium, chloride)
• Hepatic function

Exact dose (mg/m2) and cycle tracking details are not available in current raw sources. Prescription records should be obtained and ingested.